Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

An Aptamer against MNK1 for Non-Small Cell Lung Cancer Treatment

  • Carrión-Marchante, Rebeca
  • Pinto-Díez, Celia
  • Klett-Mingo, José Ignacio
  • Palacios, Esther
  • Barragán-Usero, Miriam
  • Pérez-Morgado, M. Isabel
  • Pascual-Mellado, Manuel
  • Alcalá, Sonia
  • Ruiz-Cañas, Laura
  • Sainz, Bruno Jr.
  • González, Víctor M.
  • Martín, M. Elena
Lung cancer is the leading cause of cancer-related death worldwide. Its late diagnosis and consequently poor survival make necessary the search for new therapeutic targets. The mitogen-activated protein kinase (MAPK)-interacting kinase 1 (MNK1) is overexpressed in lung cancer and correlates with poor overall survival in non-small cell lung cancer (NSCLC) patients. The previously identified and optimized aptamer from our laboratory against MNK1, apMNKQ2, showed promising results as an antitumor drug in breast cancer in vitro and in vivo. Thus, the present study shows the antitumor potential of apMNKQ2 in another type of cancer where MNK1 plays a significant role, such as NSCLC. The effect of apMNKQ2 in lung cancer was studied with viability, toxicity, clonogenic, migration, invasion, and in vivo efficacy assays. Our results show that apMNKQ2 arrests the cell cycle and reduces viability, colony formation, migration, invasion, and epithelial-mesenchymal transition (EMT) processes in NSCLC cells. In addition, apMNKQ2 reduces tumor growth in an A549-cell line NSCLC xenograft model. In summary, targeting MNK1 with a specific aptamer may provide an innovative strategy for lung cancer treatment., R.C.-M. was supported for predoctoral contracts (PEJD 2016-BMD-2145 and 2018-BMD-9201) from the Community of Madrid and grant RTC2019-07227-1. M.E.M. and V.M.G. are researchers from FIBio-HRC supported by Consejeria de Sanidad (CAM). This work was supported by grants RTC2019-07227-1 and PID2019-105417RB-I00, funded by MCIN/AEI/10.13039/501100011033 (Ministry of Economy and Competitiveness, Spain)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Platinum iodido drugs show potential anti-tumor activity, affecting cancer cell metabolism and inducing ROS and senescence in gastrointestinal cancer cells

  • Melones-Herrero, Jorge
  • Alcalá, Sonia
  • Ruiz-Cañas, Laura
  • Benitez-Buelga, Carlos
  • Batres-Ramos, Sandra
  • Calés, Carmela
  • Lorenzo, Óscar
  • Perona Abellón, Rosario
  • Quiroga, Adoración G.
  • Sainz, Bruno Jr.
  • Sánchez-Pérez, Isabel
Cisplatin-based chemotherapy has associated clinical disadvantages, such as high toxicity and resistance. Thus, the development of new antitumor metallodrugs able to overcome different clinical barriers is a public healthcare priority. Here, we studied the mechanism of action of the isomers trans and cis-[PtI2(isopropylamine)2] (I5 and I6, respectively) against gastrointestinal cancer cells. We demonstrate that I5 and I6 modulate mitochondrial metabolism, decreasing OXPHOS activity and negatively affecting ATP-linked oxygen consumption rate. Consequently, I5 and I6 generated Reactive Oxygen Species (ROS), provoking oxidative damage and eventually the induction of senescence. Thus, herein we propose a loop with three interconnected processes modulated by these iodido agents: (i) mitochondrial dysfunction and metabolic disruptions; (ii) ROS generation and oxidative damage; and (iii) cellular senescence. Functionally, I5 reduces cancer cell clonogenicity and tumor growth in a pancreatic xenograft model without systemic toxicity, highlighting a potential anticancer complex that warrants additional pre-clinical studies., This research was funded by PID2019-106220RB100, RTC2019-007227-1 granted by MICIU/ AEI / 10.13039/501100011033, and PID2022-137373OB-I00 granted by MICIU/ AEI / 10.13039/501100011033 / FEDER, UE. This study was supported by ISCIII FIS grants PI20/0335 (RP) and PI21/01110 (BSJ), co-financed through Fondo Europeo de Desarrollo Regional (FEDER) ’Una manera de hacer Europa’. JMH was supported by a grant FPI-UAM 2021 from Universidad Autónoma de Madrid (Molecular BioSciences PhD program). We thank Gonzalo Vílchez and Sofia Figueiras for their contribution to this work via Comunidad de Madrid grants PEJ-2020-AI/BMD-18538; PEJ-2021-TL/BMD-22441., Peer reviewed